« Return to News | Drug Sponsors

Sangart to create 250 jobs at Cork facility

Tuesday, August 23, 2011 01:30 PM

A total 250 jobs are to be created through the establishment of a pharmaceutical manufacturing facility in Carrigtwohill, Co Cork, according to the Irish Times.

Last month San Diego-based Sangart announced plans to hire 120 people at the facility in east Cork. However, the US company revised its figures and plans to double the workforce at the plant.

The facility will serve as Sangart’s European headquarters, and the sales and manufacturing base in Europe for its MP4OX and MP4CO therapies.

Brian O’Callaghan, the Cork-born, US-based chief executive of Sangart, expects to break ground on the site by the end of the year. It is hoped the plant will be fully functional by 2013.

“The need for oxygen therapeutic agents such as MP4OX and MP4CO is a global one, and our manufacturing investment in Ireland is an important element of preparing for the potential future marketing of our therapies,” said O’Callaghan.

Donald Brown, Sangart’s chief operations officer, cited Ireland’s business-friendly environment and talent pool as key factors in the firm’s decision to locate here.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.